HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network

EMBO Molecular Medicine

Volumn 6, Issue 5, 2014, Pages 651-661

  Ramos Montoya, Antonio ^a   Lamb, Alastair D ^a,b   Russell, Roslin ^a   Carroll, Thomas ^a   Jurmeister, Sarah ^a   Galeano Dalmau, Nuria ^a   Massie, Charlie E ^a   Boren, Joan ^a   Bon, Helene ^a   Theodorou, Vasiliki ^a,f   Vias, Maria ^a   Shaw, Greg L ^a,b   Sharma, Naomi L ^a,b,h   Ross Adams, Helen ^a   Scott, Helen E ^a   Vowler, Sarah L ^a   Howat, William J ^a   Warren, Anne Y ^a,b   Wooster, Richard F ^c,g   Mills, Ian G ^a,d,e   Neal, David E ^a,b   more..

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c Cancer Metabolism Drug Discovery Oncology R and D   (United States)

^d UNIVERSITY OF OSLO   (Norway)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f INSTITUTE OF MOLECULAR BIOLOGY AND BIOTECHNOLOGY   (Greece)

^g Blend Therapeutics   (United States)

^h UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Androgen receptor; Castrate resistant prostate cancer; Gene expression signature; HES6; PLK1

Indexed keywords

ANDROGEN RECEPTOR; BICALUTAMIDE; GSK 461364A; POLO LIKE KINASE 1; PROTEIN SERINE THREONINE KINASE INHIBITOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR HES6; UNCLASSIFIED DRUG; AR PROTEIN, HUMAN; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; CELL CYCLE PROTEIN; E2F1 PROTEIN, HUMAN; HES6 PROTEIN, HUMAN; REPRESSOR PROTEIN;

ANDROGEN INSENSITIVITY SYNDROME; ARTICLE; BINDING SITE; CANCER INHIBITION; CASTRATION RESISTANT PROSTATE CANCER; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; DRUG MECHANISM; ENZYME ACTIVATION; FLUORESCENCE ACTIVATED CELL SORTING; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GLEASON SCORE; GROWTH INHIBITION; HUMAN; HUMAN TISSUE; LIGAND BINDING; LNCAP CELL LINE; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE C MYC; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR GROWTH; UPREGULATION; ANIMAL; DISEASE MODEL; DNA SEQUENCE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; PATHOPHYSIOLOGY; PROSTATE TUMOR;

ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL CYCLE PROTEINS; DISEASE MODELS, ANIMAL; E2F1 TRANSCRIPTION FACTOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; MALE; MICE; MOLECULAR SEQUENCE DATA; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; REPRESSOR PROTEINS; SEQUENCE ANALYSIS, DNA;

EID: 84899932412     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.1002/emmm.201303581     Document Type: Article

References (47)

1. Azzi L, El-Alfy M, Labrie F (2006) Gender differences and effects of sex steroids and dehydroepiandrosterone on androgen and oestrogen alpha receptors in mouse sebaceous glands. Br J Dermatol 154: 21-27
2. Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, Wang Y, Sheikh KL, Terry S, Tagawa ST et al (2011) Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 1: 487-495
3. Bernard D, Pourtier-Manzanedo A, Gil J, Beach DH (2003) Myc confers androgen-independent prostate cancer cell growth. J Clin Invest 112: 1724-1731
4. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364: 1995-2005
5. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376: 1147-1154
6. Cam H, Dynlacht BD (2003) Emerging roles for E2F: beyond the G1/S transition and DNA replication. Cancer Cell 3: 311-316
7. Chen Y, Chi P, Rockowitz S, Iaquinta PJ, Shamu T, Shukla S, Gao D, Sirota I, Carver BS, Wongvipat J et al (2013) ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nat Med 19: 1023-1029
8. Clegg NJ, Couto SS, Wongvipat J, Hieronymus H, Carver BS, Taylor BS, Ellwood-Yen K, Gerald WL, Sander C, Sawyers CL (2011) MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors. PLoS ONE 6: e17449
9. CRUK (2010) Cancer Research UK cancerstats. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/prostate/incidence/
10. Cutress ML, Whitaker HC, Mills IG, Stewart M, Neal DE (2008) Structural basis for the nuclear import of the human androgen receptor. J Cell Sci 121: 957-968
11. Cuzick J, Swanson GP, Fisher G, Brothman AR, Berney DM, Reid JE, Mesher D, Speights VO, Stankiewicz E, Foster CS et al (2011) Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol 12: 245-255
12. Gilmartin AG, Bleam MR, Richter MC, Erskine SG, Kruger RG, Madden L, Hassler DF, Smith GK, Gontarek RR, Courtney MP et al (2009) Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis. Cancer Res 69: 6969-6977
13. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC et al (2012) The mutational landscape of lethal castration-resistant prostate cancer. Nature 487: 239-243
14. Hartman J, Lam EW, Gustafsson JA, Strom A (2009) Hes-6, an inhibitor of Hes-1, is regulated by 17beta-estradiol and promotes breast cancer cell proliferation. Breast Cancer Res 11: R79
15. Hellerstedt BA, Pienta KJ (2002) The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 52: 154-179
16. Hobisch A, Fritzer A, Comuzzi B, Fiechtl M, Malinowska K, Steiner H, Bartsch G, Culig Z (2006) The androgen receptor pathway is by-passed in prostate cancer cells generated after prolonged treatment with bicalutamide. Prostate 66: 413-420
17. Kageyama R, Ohtsuka T, Hatakeyama J, Ohsawa R (2005) Roles of bHLH genes in neural stem cell differentiation. Exp Cell Res 306: 343-348
18. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363: 411-422
19. Lamb AD, Massie CE, Neal DE (2014) The transcriptional programme of the androgen receptor (AR) in prostate cancer. BJU Int 113: 358-366
20. Machanick P, Bailey TL (2011) MEME-ChIP: motif analysis of large DNA datasets. Bioinformatics 27: 1696-1697
21. Malone CM, Domaschenz R, Amagase Y, Dunham I, Murai K, Jones PH (2011) Hes6 is required for actin cytoskeletal organization in differentiating C2C12 myoblasts. Exp Cell Res 317: 1590-1602
22. Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L, Warren A, Scott H, Madhu B, Sharma N et al (2011) The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J 30: 2719-2733
23. Mills IG (2014) Maintaining and reprogramming genomic androgen receptor activity in prostate cancer. Nat Rev Cancer 14: 187-198
24. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E et al (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34: 267-273
25. Murai K, Philpott A, Jones PH (2011) Hes6 is required for the neurogenic activity of neurogenin and NeuroD. PLoS ONE 6: e27880
26. Murai K, Vernon AE, Philpott A, Jones P (2007) Hes6 is required for MyoD induction during gastrulation. Dev Biol 312: 61-76
27. Nelius T, Filleur S, Yemelyanov A, Budunova I, Shroff E, Mirochnik Y, Aurora A, Veliceasa D, Xiao W, Wang Z et al (2007) Androgen receptor targets NFkappaB and TSP1 to suppress prostate tumor growth in vivo. Int J Cancer 121: 999-1008
28. Nilsson S, O'BryanTear C, Bolstad B, Lokna A, Parker CC (2011) Alkaline phosphatase (ALP) normalization and overall survival in patients with bone metastases from castration-resistant (CRPC) treated with radium-223 [abstract]. J Clin Oncol 29: A4620
29. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520
30. Pienta KJ, Smith DC (2005) Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin 55: 300-318; quiz 323-305
31. Qi J, Nakayama K, Cardiff RD, Borowsky AD, Kaul K, Williams R, Krajewski S, Mercola D, Carpenter PM, Bowtell D et al (2010) Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. Cancer Cell 18: 23-38
32. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S et al (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368: 138-148
33. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367: 1187-1197
34. Sharma A, Yeow WS, Ertel A, Coleman I, Clegg N, Thangavel C, Morrissey C, Zhang X, Comstock CE, Witkiewicz AK et al (2010) The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest 120: 4478-4492
35. Sharma NL, Massie CE, Ramos-Montoya A, Zecchini V, Scott HE, Lamb AD, MacArthur S, Stark R, Warren AY, Mills IG et al (2013) The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. Cancer Cell 23: 35-47
36. Snoek R, Cheng H, Margiotti K, Wafa LA, Wong CA, Wong EC, Fazli L, Nelson CC, Gleave ME, Rennie PS (2009) In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors. Clin Cancer Res 15: 39-47
37. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102: 15545-15550
38. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131: 861-872
39. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B et al (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18: 11-22
40. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC, Chung LW (1994) Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 54: 2577-2581
41. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R et al (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644-648
42. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ et al (2005) Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8: 393-406
43. Ventura A, Meissner A, Dillon CP, McManus M, Sharp PA, Van Parijs L, Jaenisch R, Jacks T (2004) Cre-lox-regulated conditional RNA interference from transgenes. Proc Natl Acad Sci USA 101: 10380-10385
44. Vias M, Massie CE, East P, Scott H, Warren A, Zhou Z, Nikitin AY, Neal DE, Mills IG (2008) Pro-neural transcription factors as cancer markers. BMC Med Genomics 1: 17
45. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M et al (2009) Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138: 245-256
46. Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, Wu X, Stack EC, Loda M, Liu T et al (2012) EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science 338: 1465-1469
47. Yap TA, Zivi A, Omlin A, de Bono JS (2011) The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol 8: 597-610